Why are anticancer drugs expensive? Wei Jian Committee: high pricing for enterprises to take back the early investment

category:Society
 Why are anticancer drugs expensive? Wei Jian Committee: high pricing for enterprises to take back the early investment


The main reason for the high drug price is anticancer drugs. Yu Jingjin said that there are several reasons for the high cost of anticancer drugs. First, the R & D investment is big. In recent years, all sides have increased investment in anticancer drug research and development. The success rate of new product R & D is less than 2%, and the average cost exceeds $700 million. Enterprises need to recover the early investment through high pricing. The two is the limited security. The basic medical insurance standards for urban and rural residents are less than 700 yuan per person. After the insurance is reimbursed for major diseases, some patients burden of self charge is still very heavy, and the role of supplementary insurance, commercial insurance and charity assistance is not enough. Three, the survival period of the tumor was prolonged. With the progress of cancer prevention and control technology and the speed of new drug listing, the proportion of cancer patients diagnosed in 2014 and the survival time for more than 5 years is more than 40%, and the cost of anti-cancer drugs is further promoted. At the same time, Yu Jingjin mentioned that, in order to make the masses with higher quality and lower price drugs, according to the State Council, the State Health Planning Commission and the Ministry of human resources and social security have organized the national drug price trial and the national medical insurance catalog negotiations, respectively, 39 since 2016. The average price of the negotiated variety has been reduced by more than 50%, and has been included in the national health insurance directory, including 17 anticancer drugs. Since July 1, 2016 and October 1, 2017, two batches of drugs have been distributed on the platform of centralized purchase of drugs at the provincial level, and centralized procurement on the Internet by medical institutions. As of April 18th this year, 17 kinds of anti-cancer drugs in the two batch of negotiations were reduced by 4 billion 170 million yuan because of price reduction, plus part of the reimbursement for medical insurance catalogues, and a total of 6 billion 240 million yuan for patients to reduce the burden of medicine. According to the work arrangement of the State Council, Yu Jingjin said that the zero tariff of imported drugs will be formally implemented since May 1st to transmit this good policy to the clinical terminal of cancer patients. The national health and Health Commission and the relevant departments have studied centralized procurement, medical insurance sales, and speed up the import and export of innovative drugs. The comprehensive follow-up measures of cancer drug cost, combination of remote and near integration, and supporting policies have been promoted to form a synergy to enlarge the benefit of the people. Source: surging news editor: Qiao Jing _NN6607 At the same time, Yu Jingjin mentioned that, in order to make the masses with higher quality and lower price drugs, according to the State Council, the State Health Planning Commission and the Ministry of human resources and social security have organized the national drug price trial and the national medical insurance catalog negotiations, respectively, 39 since 2016. The average price of the negotiated variety has been reduced by more than 50%, and has been included in the national health insurance directory, including 17 anticancer drugs. Since July 1, 2016 and October 1, 2017, two batches of drugs have been distributed on the platform of centralized purchase of drugs at the provincial level, and centralized procurement on the Internet by medical institutions. As of April 18th this year, 17 kinds of anti-cancer drugs in the two batch of negotiations were reduced by 4 billion 170 million yuan because of price reduction, plus part of the reimbursement for medical insurance catalogues, and a total of 6 billion 240 million yuan for patients to reduce the burden of medicine. According to the work arrangement of the State Council, Yu Jingjin said that the zero tariff of imported drugs will be formally implemented since May 1st to transmit this good policy to the clinical terminal of cancer patients. The national health and Health Commission and the relevant departments have studied centralized procurement, medical insurance sales, and speed up the import and export of innovative drugs. The comprehensive follow-up measures of cancer drug cost, combination of remote and near integration, and supporting policies have been promoted to form a synergy to enlarge the benefit of the people.